(1) EADO session
Question about prevention and early detection of melanoma

Prevention

• What is the real role of UV in the different types of melanoma?
  Martin Weinstock (USA)

• Do epidemiological trends of melanoma suggest an efficacy of sun prevention?
  Luigi Naldi (Italy)

Early detection and surveillance of nevi

• Is education to the community cost effective for early detection of melanoma?
  Alex Stratigos (Greece)
  

• Monitoring techniques (mole mapping, computerized dermoscopy …):
  cost-effective or time consuming?
  Michael Binder (Austria)

• Dysplastic nevi in 2008
  Josep Malvehy (Spain)

• Kinetics of melanoma growth: an impact on early detection?
  Jean-Jacques Grob (France)

(2) ICATMM session
Adjuvant therapy: what have we learnt?

How can we select subgroups for adjuvant therapy?

• Risk markers: molecular profile of primary tumors
  Alain Spatz (France)

• Risk markers: surgical staging
  Vernon Sondak (USA)

• Risk markers: disease staging: present and future
  Jeffrey Gerschenwald (USA)

• Response predictors: auto-immunity
  Helen Gogas (Greece)

• Response predictors: tumor markers and markers of residual disease
  Selma Ugurel (Germany)

• Detection of residual disease during surveillance: imaging and ultrasound
  Philippe Saiag (France)

Current status of the adjuvant therapy

• Surgical adjuvant therapy: elective node dissection according to sentinel node status: Pro
  Merrick Ross (USA)

• Surgical adjuvant therapy: elective node dissection according to sentinel node status: Against
  Joseph Meirion Thomas (United Kingdom)

• Adjuvant therapy with Interferons: 20 years of Interferons α
  Alexander Eggermont (The Netherlands)

• Adjuvant therapy with Interferons: pegylated interferons
  Claus Garbe (Germany)

Free communications

(3) EADO and ICATMM session
New strategies: from first results in metastatic melanoma to the application in the adjuvant therapy

Targeted therapies and combinations

• Targeting kinase and signalling pathways
  Paul Nathan (United Kingdom)
  

• Targeting integrins and angiogenesis
  Jens Gille (Germany)

• Targeting resistance to apoptosis
  Hubert Pehamberger (Austria)

• Targeting histone deacetylase and DNA hypermethylation
  Peter Hersey (Australia)

• Targeting heat shock proteins, chaperones and proteasomes
  Keith Flaherty (USA)

• Synthesis:What potential place in the palliative and adjuvant strategy?
  (results of clinical trials)
  Axel Hauschild (Germany)

New development in chemotherapy and combinations

• Recent advances in chemotherapy of melanoma and chemo-immunotherapy
  Sanjiv Agarwala (USA)

• Combining chemotherapy and targeted therapy
  Alessandro Testori (Italy)

New development in immunotherapy and potential application in adjuvant setting

• Future therapeutic avenues based on immune response against melanoma
  Daniel Olive (France)

• New approaches using cytokines
  John Kirkwood (USA)

• Vaccination dendritic cells approach
  Dirk Schadendorf (Germany)

• What’s new in adoptive immunotherapy
  Brigitte Dreno (France)

• Anti CTLA4 and combination
  Antoni Ribas (USA)

• Place of natural immunity modulation (TLR agonists, …)
  Reinhard Dummer (Switzerland)

• Using sentinel node as a target for adjuvant therapy?
  Tanja de Gruijl (The Netherlands)

• Synthesis:What potential place in the palliative and adjuvant strategy?
  Caroline Robert (France)

• Systemic treatment of metastatic melanoma. Quo vadis oncologist?
  Spyros Retsas (United Kingdom)

Free communications

(4) EADO session

Non surgical treatments of non melanoma skin cancers (actinic keratoses, invasive squamous cell carcinoma and basal cell carcinoma)

• Is field cancerization more than a concept?
  Eggert Stockfleth (Germany)
• Do we need to treat all actinic keratoses? Identification of people at risk?
  Martin Weinstock (USA)
• Best indications of Solaraze
  Hubert Pehamberger (Austria)
• Best indications of 5 FU
  Eggert Stockfleth (Germany)
• Best indications of Imiquimod
  Sergio Chimenti (Italy)
• Best indications of Cryotherapy, Lasers and PTD
  Marie-Aleth Richard (France)
  

Genetic counselling in melanoma

• Genetics of melanoma
  Julia Newton-Bishop (United Kingdom)
• What practical impact of genetic counselling?
  Ketty Perris (Italy)

Managing cutaneous lymphoma

• Better understanding how to classify common and rare forms of skin lymphoma
  Marie Beylot-Barry (France)
• Physiopathology of mycosis fungoides
  Martine Bagot (France)
• Recent results in the treatment of mycosis fungoides
  (chemotherapies, retinoids, targeted therapies…)
  Reinhard Dummer (Switzerland)
• Refractory T cell skin lymphoma
  Roland Kaufmann (Germany)
• Managing pseudo-lymphomas and low grades lymphomas
  Hervé Bachelez (France)
• Selection of strategies in cutaneous B cell lymphomas
  Reda Bouabdallah (France)